Sporoderm-Broken Spores of Ganoderma lucidum Sensitizes Ovarian Cancer to Cisplatin by ROS/ERK Signaling and Attenuates Chemotherapy-Related Toxicity.

Ganoderma lucidum

OncologyImmune supportMetabolic healthLiver support

SpeciesReishi, Lingzhi

JournalFrontiers in pharmacology

Year2022

Metadata-grounded summary

Article summary

Metadata-grounded summary: This research article indexes research on Ganoderma lucidum in Frontiers in pharmacology in 2022. MycoData maps the paper to oncology, immune support, metabolic health, liver support based on its title, species context, article metadata, and study classification.

Citation

Cen K, Chen M, He M, Li Z, Song Y, Liu P, et al. (2022). Sporoderm-Broken Spores of Ganoderma lucidum Sensitizes Ovarian Cancer to Cisplatin by ROS/ERK Signaling and Attenuates Chemotherapy-Related Toxicity. Frontiers in pharmacology https://doi.org/10.3389/fphar.2022.826716 PMID: 35264959

Open citation